Showing 1 - 10 of 12
The state of publicly funded science is in peril. Instead, new biomedical research efforts — in particular, the recent funding of a “Cancer Moonshot” — have focused on employing public-private partnerships, joint ventures between private industry and public agencies, as being more...
Persistent link: https://www.econbiz.de/10012934524
Whether the E.U. Trade Secrets Directive sufficiently and appropriately covers cutting-edge complex technologies is of critical interest to policy-makers, scientists, and commercial developers alike. One such technology — adaptive immune receptor repertoire sequencing, or AIRR-seq — raises...
Persistent link: https://www.econbiz.de/10014111403
Persistent link: https://www.econbiz.de/10014153705
“Biohacking” has emerged as a cultural and scientific phenomenon. Although there is no consensus on the precise definition of “biohacking,” the term generally describes biological investigations and interventions that are conducted outside of typical scientific settings by individuals...
Persistent link: https://www.econbiz.de/10014103140
Physicians have long worried about gene patents’ potential to restrict their medical practices. Fortune and hindsight have proven these worries exaggerated both in the UK and elsewhere. Neither current nor future medical practices appear to be impinged by gene patents, although they may be...
Persistent link: https://www.econbiz.de/10014103220
The COVID-19 crisis has starkly illustrated both the strengths and limitations of U.S. biomedical innovation institutions as deployed to fight a pandemic. These innovation institutions include not just intellectual property law, but also other legal systems that structure incentives for...
Persistent link: https://www.econbiz.de/10014081533
The Broad Institute's recent licensing of its gene editing patent portfolio demonstrates how licenses can be used to restrict controversial applications of emerging technologies while society deliberates their implications
Persistent link: https://www.econbiz.de/10014123375
Persistent link: https://www.econbiz.de/10013063449
Antibodies constitute a staggering $145 billion annual market—an amount projected to almost double by 2026. Consequently, patents covering antibodies are among the most valuable in the patent system. But antibody patents are being struck down left and right, victims of the Federal Circuit’s...
Persistent link: https://www.econbiz.de/10013305587
As the devastating COVID-19 pandemic first swept the globe, it posed a crucial test of biomedical innovation institutions. Containing the virus required developing new technologies including diagnostic tests, pharmaceuticals, and vaccines; manufacturing these technologies at enormous scale; and...
Persistent link: https://www.econbiz.de/10013224537